Welcome to our dedicated page for Cvs Health SEC filings (Ticker: CVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CVS Health Corporation filings document formal disclosures for a NYSE-listed health care company with retail pharmacy, pharmacy benefit management, health insurance, clinic, specialty pharmacy, and consumer wellness operations. Recent Form 8-K reports furnish quarterly and annual operating results, financial guidance, investor-day materials, and material events tied to business performance.
The company's proxy materials and other filings describe board composition, director independence, committee assignments, executive compensation, stockholder voting matters, and governance practices. Additional 8-K disclosures record board leadership changes, common-stock registration information, and Omnicare subsidiary chapter 11 proceedings and related financing disclosures.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.
CVS Health Corporation reports that its wholly owned indirect subsidiary Omnicare, LLC and certain related entities have voluntarily begun chapter 11 bankruptcy proceedings in the U.S. to address issues arising from recent litigation in the U.S. District Court for the Southern District of New York, where the court imposed what Omnicare describes as excessive monetary damages.
Omnicare plans to use the court-supervised process to handle broader financial challenges in the long-term care pharmacy industry and to consider restructuring options, including a potential standalone restructuring or sale. Omnicare has arranged debtor-in-possession financing with a third party, which, once approved by the court and combined with ongoing operating cash flows, is expected to provide enough liquidity for the Omnicare entities to continue operating while the chapter 11 process proceeds.
Prem S. Shah, EVP and Group President at CVS Health (CVS), surrendered 6,995 shares on 08/31/2025 to satisfy withholding taxes from the vesting and settlement of a restricted stock unit award. The shares were recorded at a price of $73.15 and, after the transaction, Mr. Shah beneficially owned 60,631.677 shares directly. The Form 4 was signed on 09/02/2025 and reflects a routine insider tax-withholding disposition rather than an open-market sale.
Insider transaction: Tilak Mandadi, Executive Vice President and Chief Experience & Technology Officer at CVS Health (CVS), reported a transaction on 08/31/2025 in which 12,834 shares of CVS common stock were disposed at a price of $73.15 per share. The filing states these shares were surrendered to cover withholding taxes upon vesting and settlement of restricted stock units, a routine payroll tax withholding mechanism for equity compensation. Following the transaction Mandadi beneficially owns 63,952 shares directly.
Anne A. Finucane, a director of CVS Health (CVS), reported a sale of company stock that was filed on Form 4. The filing shows a transaction dated 08/20/2025 in which 7,500 shares of Common Stock were disposed of at a reported price of $71.02 per share under transaction code S(1). After the reported sale, the filing lists 22,156 shares beneficially owned indirectly through a trust. The form includes an explanatory note stating the sale was not timely reported due to an administrative error. The document is signed by Anne M. Finucane on 08/29/2025.
CVS Health Corporation: This Form 144 notifies a proposed sale of 7,500 shares of CVS common stock through Merrill Lynch on the NYSE with an aggregate market value of $532,275, scheduled approximately for 08/20/2025. The filer reports that these shares were received as director compensation across multiple grant dates between 2012 and 2022, totaling specific lots of 1,428; 2,222; 1,546; 2,099; and 205 shares. No securities were reported sold in the past three months. The notice includes the standard representation that the selling person does not possess undisclosed material adverse information.
CVS Health Corporation filed an 8-K reporting documentation related to a debt offering process. The filing references an Underwriting Agreement dated August 11, 2025 naming Barclays Capital Inc., J.P. Morgan Securities LLC and Wells Fargo Securities, LLC as representatives of the underwriters. The forms of four notes with maturities labeled 2032, 2035, 2055 and 2065 are included as exhibits, along with the opinion and consent of Wachtell, Lipton, Rosen & Katz. The cover page Inline XBRL data is noted as filed. The filing is signed by Brian Newman, Executive Vice President and Chief Financial Officer on August 15, 2025.